Omission of lymphadenectomy is possible for low-risk corpus cancer

European Journal of Surgical Oncology

Volumn 33, Issue 1, 2007, Pages 86-90

  Hidaka, T ^a   Kato, K ^b   Yonezawa, R ^a   Shima, T ^a   Nakashima, A ^a   Nagira, K ^a   Nakamura, T ^a   Saito, S ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Takaoka City Hospital   (Japan)

Author keywords

Endometrial carcinoma; Low risk; Lymph node metastasis; Lymphadenectomy; Pelvic lymph node; Survival rate

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ABDOMINAL HYSTERECTOMY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CANCER GRADING; CANCER INVASION; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; FEMALE; FREEZING; HUMAN; HUMAN TISSUE; INCIDENCE; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHADENECTOMY; LYMPHEDEMA; MAJOR CLINICAL STUDY; MEDICAL RECORD; MORBIDITY; MYOMETRIUM; OPERATION DURATION; OVERALL SURVIVAL; PELVIS LYMPH NODE; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY;

ADULT; AGED; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33846386839     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.09.035     Document Type: Article

References (31)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics 2005. CA Cancer J Clin 55 (2005) 10-30
2. Podczaski E., Kaminski P., Gurski K., et al. Detection and patterns of treatment failure in 300 consecutive cases of "early" endometrial cancer after primary surgery. Gynecol Oncol 47 (1992) 323-327
3. Carey M.S., O'Connell G.J., Johanson C.R., et al. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. Gynecol Oncol 57 (1995) 138-144
4. FIGO stages - 1988 revision. Gynecol Oncol 35 (1989) 125-126
5. Morrow C.P., Bundy B.N., Kurman R.J., et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40 (1991) 55-65
6. Mariani A., Webb M.J., Keeney G.L., Haddock M.G., Calori G., and Podratz K.C. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?. Am J Obstet Gynecol 182 (2000) 1506-1519
7. Creasman W.T., Morrow C.P., Bundy B.N., Homesley H.D., Graham J.E., and Heller P.B. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer 60 (1987) 2035-2041
8. Piver M.S., and Hempling R.E. A prospective trial of postoperative vaginal radium/cesium for grade 1-2 less than 50% myometrial invasion and pelvic radiation therapy for grade 3 or deep myometrial invasion in surgical stage I endometrial adenocarcinoma. Cancer 66 (1990) 1133-1138
9. Trimble E.L., Kosary C., and Park R.C. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol 71 (1998) 340-343
10. Goff B.A., and Rice L.W. Assessment of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol Oncol 38 (1990) 46-48
11. Yokoyama Y., Maruyama H., Sato S., and Saito Y. Indispensability of pelvic and paraaortic lymphadenectomy in endometrial cancers. Gynecol Oncol 64 (1997) 411-417
12. Frumovitz M., Singh D.K., Meyer L., et al. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol 95 (2004) 463-468
13. Takeshima N., Hirai Y., Tanaka N., Yamawaki T., Yamauchi K., and Hasumi K. Pelvic lymph node metastasis in endometrial cancer with no myometrial invasion. Obstet Gynecol 88 (1996) 280-282
14. Ben-Shachar I., Pavelka J., Cohn D.E., et al. Surgical staging for patients presenting with grade 1 endometrial carcinoma. Obstet Gynecol 105 (2005) 487-493
15. Boronow R.C., Morrow C.P., Creasman W.T., et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol 63 (1984) 825-832
16. Mariani A., Webb M.J., Keeney G.L., Aletti G., and Podratz K.C. Endometrial cancer: predictors of peritoneal failure. Gynecol Oncol 89 (2003) 236-242
17. Schink J.C., Rademaker A.W., Miller D.S., and Lurain J.R. Tumor size in endometrial cancer. Cancer 67 (1991) 2791-2794
18. Loeffler J.S., Rosen E.M., Niloff J.M., Howes A.E., and Knapp R.C. Whole abdominal irradiation for tumors of the uterine corpus. Cancer 61 (1988) 1332-1335
19. Gibbons S., Martinez A., Schray M., et al. Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma. Int J Radiat Oncol Biol Phys 21 (1991) 1019-1025
20. Thigpen J.T., Brady M.F., Homesley H.D., et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 22 (2004) 3902-3908
21. Aapro M.S., van Wijk F.H., Bolis G., et al. European organisation for research and treatment of cancer gynaecological cancer group. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 14 (2003) 441-448
22. Scudder S.A., Liu P.Y., Wilczynski S.P., et al. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecol Oncol 96 (2005) 610-615
23. Fleming G.F., Brunetto V.L., Cella D., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 22 (2004) 2159-2166
24. Hoskins P.J., Swenerton K.D., Pike J.A., et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 19 (2001) 4048-4053
25. Dimopoulos M.A., Papadimitriou C.A., Georgoulias V., et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol 78 (2000) 52-57
26. Lissoni A., Gabriele A., Gorga G., et al. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol 8 (1997) 969-972
27. Larson D.M., Johnson K., and Olson K.A. Pelvic and para-aortic lymphadenectomy for surgical staging of endometrial cancer: morbidity and mortality. Obstet Gynecol 79 (1992) 998-1001
28. Franchi M., Ghezzi F., Riva C., Miglierina M., Buttarelli M., and Bolis P. Postoperative complications after pelvic lymphadenectomy for the surgical staging of endometrial cancer. J Surg Oncol 78 (2001) 232-237
29. Framarino dei Malatesta M.L., Pecorini F., Paolucci A., et al. Complications in the surgical treatment of carcinoma of the endometrium. Clin Exp Obstet Gynecol 21 (1994) 30-32
30. Brinton L.A., Berman M.L., Mortel R., et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 167 (1992) 1317-1325
31. Folsom A.R., Kaye S.A., Potter J.D., and Prineas R.J. Association of incident carcinoma of the endometrium with body weight and fat distribution in older women: early findings of the Iowa Women's Health Study. Cancer Res 49 (1989) 6828-6831